152 related articles for article (PubMed ID: 28166391)
1. Lactosamine-Based Derivatives as Tools to Delineate the Biological Functions of Galectins: Application to Skin Tissue Repair.
Dion J; Deshayes F; Storozhylova N; Advedissian T; Lambert A; Viguier M; Tellier C; Dussouy C; Poirier F; Grandjean C
Chembiochem; 2017 Apr; 18(8):782-789. PubMed ID: 28166391
[TBL] [Abstract][Full Text] [Related]
2. Defining the potential of aglycone modifications for affinity/selectivity enhancement against medically relevant lectins: synthesis, activity screening, and HSQC-based NMR analysis.
Rauthu SR; Shiao TC; André S; Miller MC; Madej É; Mayo KH; Gabius HJ; Roy R
Chembiochem; 2015 Jan; 16(1):126-39. PubMed ID: 25407851
[TBL] [Abstract][Full Text] [Related]
3. Biophysical and structural characterization of mono/di-arylated lactosamine derivatives interaction with human galectin-3.
Atmanene C; Ronin C; Téletchéa S; Gautier FM; Djedaïni-Pilard F; Ciesielski F; Vivat V; Grandjean C
Biochem Biophys Res Commun; 2017 Jul; 489(3):281-286. PubMed ID: 28554839
[TBL] [Abstract][Full Text] [Related]
4. Development of a Sensitive Microarray Platform for the Ranking of Galectin Inhibitors: Identification of a Selective Galectin-3 Inhibitor.
Dion J; Advedissian T; Storozhylova N; Dahbi S; Lambert A; Deshayes F; Viguier M; Tellier C; Poirier F; Téletchéa S; Dussouy C; Tateno H; Hirabayashi J; Grandjean C
Chembiochem; 2017 Dec; 18(24):2428-2440. PubMed ID: 29024281
[TBL] [Abstract][Full Text] [Related]
5. Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors.
Salameh BA; Sundin A; Leffler H; Nilsson UJ
Bioorg Med Chem; 2006 Feb; 14(4):1215-20. PubMed ID: 16242339
[TBL] [Abstract][Full Text] [Related]
6. Role of Galectins in Tumors and in Clinical Immunotherapy.
Chou FC; Chen HY; Kuo CC; Sytwu HK
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29389859
[TBL] [Abstract][Full Text] [Related]
7. Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1.
van Hattum H; Branderhorst HM; Moret EE; Nilsson UJ; Leffler H; Pieters RJ
J Med Chem; 2013 Feb; 56(3):1350-4. PubMed ID: 23281927
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic synthesis of non-natural trisaccharides and galactosides; Insights of their interaction with galectins as a function of their structure.
Porciúncula González C; Cagnoni AJ; Mariño KV; Fontana C; Saenz-Méndez P; Irazoqui G; Giacomini C
Carbohydr Res; 2019 Jan; 472():1-15. PubMed ID: 30428394
[TBL] [Abstract][Full Text] [Related]
9. Lactulose as a novel template for anticancer drug development targeting galectins.
Kishor C; Ross RL; Blanchard H
Chem Biol Drug Des; 2018 Oct; 92(4):1801-1808. PubMed ID: 29888844
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of galectin inhibitors.
Sörme P; Kahl-Knutsson B; Wellmar U; Magnusson BG; Leffler H; Nilsson UJ
Methods Enzymol; 2003; 363():157-69. PubMed ID: 14579574
[No Abstract] [Full Text] [Related]
11. Design-functionality relationships for adhesion/growth-regulatory galectins.
Ludwig AK; Michalak M; Xiao Q; Gilles U; Medrano FJ; Ma H; FitzGerald FG; Hasley WD; Melendez-Davila A; Liu M; Rahimi K; Kostina NY; Rodriguez-Emmenegger C; Möller M; Lindner I; Kaltner H; Cudic M; Reusch D; Kopitz J; Romero A; Oscarson S; Klein ML; Gabius HJ; Percec V
Proc Natl Acad Sci U S A; 2019 Feb; 116(8):2837-2842. PubMed ID: 30718416
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of galectin expression/reactivity during wound healing in porcine skin and in cultures of epidermal cells with functional impact on migration.
Klíma J; Lacina L; Dvořánková B; Herrmann D; Carnwath JW; Niemann H; Kaltner H; André S; Motlík J; Gabius HJ; Smetana K
Physiol Res; 2009; 58(6):873-884. PubMed ID: 19093745
[TBL] [Abstract][Full Text] [Related]
13. Taloside inhibitors of galectin-1 and galectin-3.
Collins PM; Oberg CT; Leffler H; Nilsson UJ; Blanchard H
Chem Biol Drug Des; 2012 Mar; 79(3):339-46. PubMed ID: 22136701
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
Sioud M; Mobergslien A; Boudabous A; Fløisand Y
Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
[TBL] [Abstract][Full Text] [Related]
15. A Quantitative Human Red Blood Cell Agglutination Assay for Characterisation of Galectin Inhibitors.
Gasson R; Roper JA; Slack RJ
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928462
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence polarization as an analytical tool to evaluate galectin-ligand interactions.
Sörme P; Kahl-Knutsson B; Huflejt M; Nilsson UJ; Leffler H
Anal Biochem; 2004 Nov; 334(1):36-47. PubMed ID: 15464951
[TBL] [Abstract][Full Text] [Related]
17. Galectin-2 and -4, but not galectin-1, promote intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanism.
Paclik D; Lohse K; Wiedenmann B; Dignass AU; Sturm A
Inflamm Bowel Dis; 2008 Oct; 14(10):1366-72. PubMed ID: 18484670
[TBL] [Abstract][Full Text] [Related]
18. Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development.
Dussouy C; Kishor C; Lambert A; Lamoureux C; Blanchard H; Grandjean C
Chem Biol Drug Des; 2020 Oct; 96(4):1123-1133. PubMed ID: 32220037
[TBL] [Abstract][Full Text] [Related]
19. Galectin-7 in Epithelial Homeostasis and Carcinomas.
Advedissian T; Deshayes F; Viguier M
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29257082
[TBL] [Abstract][Full Text] [Related]
20. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair.
Dvořánková B; Szabo P; Lacina L; Gal P; Uhrova J; Zima T; Kaltner H; André S; Gabius HJ; Sykova E; Smetana K
Cells Tissues Organs; 2011; 194(6):469-80. PubMed ID: 21494018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
